P. Masarachia

发表

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

G. Wesolowski, G. Rodan, M. Rogers, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism.

C. Leu, G. Rodan, P. Masarachia, 1998, Endocrinology.

Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

L. Duong, Susan Y. Smith, G. Wesolowski, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The effects of three different demineralization agents on osteopontin localization in adult rat bone using immunohistochemistry

J. D. Frank, J. Seedor, R. Balena, 1993, Histochemistry.

The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats

G. Rodan, M. Gentile, J. Seedor, 1993, Calcified Tissue International.

The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat. Comparison between effects on tibiae and vertebrae.

G. Rodan, M. Gentile, J. Seedor, 1993, Bone.

Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones.

G. Rodan, R. Balena, P. Masarachia, 1996, Bone.

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

G. Rodan, P. Masarachia, A. Reszka, 2000, Archives of biochemistry and biophysics.

Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands

D. Kimmel, G. Rodan, D. Towler, 2009, The Journal of Biological Chemistry.

Discovery of the Selective Androgen Receptor Modulator MK-0773 Using a Rational Development Strategy Based on Differential Transcriptional Requirements for Androgenic Anabolism Versus Reproductive Physiology*

P. Hodor, C. Leu, D. Kimmel, 2010, The Journal of Biological Chemistry.

The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.

L. Duong, P. Masarachia, M. Pickarski, 2011, Bone.

Comparison of the therapeutic potencies of two bisphosphonates

G. Rodan, J. Seedor, R. Balena, 1992 .

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

R. Recker, D. Kimmel, L. Wehren, 2005, Current medical research and opinion.

Bone density, strength, and formation in adult cathepsin K (-/-) mice.

S. Rodan, D. Kimmel, G. Rodan, 2009, Bone.

Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways.

D. Gerhold, D. Kimmel, L. Freedman, 2005, Endocrinology.

Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis

G. Rodan, P. Masarachia, A. Reszka, 1999, The Journal of Biological Chemistry.

Cathepsin K inhibitors prevent bone loss in estrogen‐deficient rabbits

L. Duong, Susan Y. Smith, D. Kimmel, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

G. Wesolowski, G. Rodan, M. Rogers, 1999, Proceedings of the National Academy of Sciences of the United States of America.